Anbio Biotechnology annual return on equity
2023
2024
2025
Anbio Biotechnology Return on Equity (ROE) Growth & History (NNNN)
Anbio Biotechnology's return on equity was 27.05% for fiscal 2025.
View full Anbio Biotechnology company overviewAnbio Biotechnology annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 27.05% | +12.22 pp |
| 2024 | 2024-12-31 | 14.83% | −1.65 pp |
| 2023 | 2023-12-31 | 16.47% | — |
Anbio Biotechnology return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Anbio Biotechnology's return on equity increased from 16.47% to 27.05%, a change of +10.58 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anbio Biotechnology source filings ↗